The immune response behind peptide vaccination in diffuse midline glioma

Abstract

A first‐in‐human trial demonstrated that a vaccine targeting the histone mutation H3K27M can induce an immune response, in a mutation‐specific manner, in patients with diffuse midline glioma. In a recent study by Boschert et al., the same group now dissects the functional immune response triggered after effective vaccination of one of the patients, who has been in remission for over 3 years. The H3K27M peptide vaccine, named H3‐vac, induces a CD4+ T‐cell‐specific immune response in this patient and expands the repertoire of polyclonal H3K27M‐specific T‐cell receptors. A clonal H3K27M‐reactive B‐cell population was also detected in the patient's cerebrospinal fluid. Importantly, the immune response is induced across various human leukocyte antigen alleleotypes, indicating the potential efficacy of the vaccine in diverse populations. By exploring in detail the immune response linked to this patient's long‐term survival, the authors prove peptide vaccinations as a viable therapeutic approach. This paves the way for personalised therapies harnessing immunogenic T‐ and B‐cell responses against different tumour types.

Keywords

• cancer
• diffuse midline glioma
• H3K27M mutation
• immunotherapy
• neoepitope peptide vaccine